Fairness – Widespread
$45,272,228
09/01/2022
Bridgewater, New Jersey
Healthcare & Prescribed drugs
Neurotez, with a valuation of $45.2 million, is elevating funds on NetCapital. The corporate is creating a hormone substitute remedy named Memtin to deal with Leptin deficiency in Alzheimer’s sufferers. The drug will assist decelerate cognitive decline in sufferers with Alzheimer’s and different types of dementia. Neurotez has already obtained many rewards and recognitions and is backed by a wonderful staff of consultants. Nikolaos Tezapsidis based Neurotez in 2005. The present crowdfunding marketing campaign has a minimal goal of $10,000 and a most goal of $500,000. The marketing campaign proceeds shall be used for analysis and growth, advertising and marketing, compensation for managers, and authorized bills.
Abstract Revenue and Loss Assertion
|
Income |
$0 |
$0 |
|
COGS |
$0 |
$0 |
|
Tax |
$3,184 |
$1,250 |
|
|
||
|
|
||
|
Internet Earnings |
$-314,585 |
$-188,407 |
Abstract Steadiness Sheet
|
Money |
$24,783 |
$5,882 |
|
Accounts Receivable |
$0 |
$0 |
|
Complete Belongings |
$169,799 |
$164,744 |
|
Brief-Time period Debt |
$0 |
$65,356 |
|
Lengthy-Time period Debt |
$62,255 |
$0 |
|
Complete Liabilities |
$62,255 |
$65,356 |
Financials as of: 09/01/2022
Increase Historical past
| Neurotez | 11/01/2022 | Netcapital | $45,272,228 | $0 | Fairness – Widespread |
Lively |
RegCF |
| Neurotez | 03/10/2022 | StartEngine | $44,870,036 | $33,845 | Fairness – Widespread |
Funded |
RegCF |
| Neurotez | 06/24/2021 | Netcapital | $21,959,058 | $255,718 | Fairness – Widespread |
Funded |
RegCF |
| Neurotez | 02/26/2018 | Netcapital | $24,544,690 | $95,809 | Fairness – Widespread |
Funded |
RegCF |
